DLL4 and neoplasm: Yen et al establish that the combination of anti-DLL4 antibody and paclitaxel decrease BCSCs frequency and retard the tumor relapse in paclitaxel-resistant TNBCs.60 Wang et al successfully developed antibody-drug conjugates of Monomethyl auristatin E and anti-DLL4 antibody to promote tumor cell death and to achieve site-specific delivery.61